ad30e5e1-182b-4758-8e70-53e0bcf78072
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 62
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.600
- E2F_TARGETS+0.590
- PANCREAS_BETA_CELLS+0.470
- MITOTIC_SPINDLE+0.420
- MYC_TARGETS_V1+0.340
- HEDGEHOG_SIGNALING+0.310
- SPERMATOGENESIS+0.310
- WNT_BETA_CATENIN_SIGNALING+0.310
- MYC_TARGETS_V2+0.260
- UV_RESPONSE_DN+0.140
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.490
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.480
- OXIDATIVE_PHOSPHORYLATION-0.460
- IL6_JAK_STAT3_SIGNALING-0.450
- INFLAMMATORY_RESPONSE-0.450
- INTERFERON_GAMMA_RESPONSE-0.400
- NOTCH_SIGNALING-0.400
- ALLOGRAFT_REJECTION-0.360
- COMPLEMENT-0.330
- INTERFERON_ALPHA_RESPONSE-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AN-A0FY-01A-11R-A034-07 | — | B | 0.860 |
| 2 | dd75267f-824e-4ddc-9056-cdf0f500d39b | — | — | 0.859 |
| 3 | BS_HB03GSHF | medulloblastoma | — | 0.857 |
| 4 | BS_BVSW4GTG | medulloblastoma | — | 0.856 |
| 5 | SRR8613800 | — | D | 0.848 |
| 6 | TCGA-A1-A0SK-01A-12R-A084-07 | — | E | 0.847 |
| 7 | SJEPD031150_D1.RNA-Seq | EPN | EPN Tumor | 0.847 |
| 8 | TCGA-34-5927-01A-11R-1820-07 | — | cohortSQ1 | 0.846 |
| 9 | BS_AM70R8RG | medulloblastoma | — | 0.845 |
| 10 | BS_1AYRM596 | medulloblastoma | — | 0.843 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.600 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.590 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.470 | Cobimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.420 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.340 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.310 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.310 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.260 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.140 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.090 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.070 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.030 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.010 | Inavolisib | — uncovered |